New insights into the mechanism of action of immune checkpoint antibodies. Oncoimmunology Marabelle, A., Kohrt, H., Levy, R. 2014; 3 (8): e954869


Preclinical models have been developed and applied to predict the clinical efficacy of immune checkpoint antibodies. Now these models can be used to dissect the mechanisms by which such immunotherapeutic antibodies work and to build the rationale for combining immune checkpoint-targeting antibodies with potential synergistic activity in cancer patients.

View details for DOI 10.4161/21624011.2014.954869

View details for PubMedID 25610751

View details for PubMedCentralID PMC4292403